Genetic alteration regulated by microRNAs in biliary tract cancers

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 2, 2015, Pages 262-273

  Wang, Ning ^a   Xia, Shihai ^a   Chen, Kai ^a   Xiang, Xiaohui ^a   Zhu, Aijun ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Gallbladder carcinoma; Genetic alteration; microRNAs

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MICRORNA; SINGLE STRANDED RNA; UNTRANSLATED RNA;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; GALLBLADDER CANCER; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; TUMOR INVASION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; BILIARY TRACT TUMOR; GENETICS; PATHOLOGY;

BILIARY TRACT NEOPLASMS; HUMANS; MICRORNAS;

EID: 84955183728     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.015     Document Type: Review

References (100)

1. Shaib Y, El-Serag HB. The epidemiology of cholan-giocarcinoma. Semin Liver Dis 2004;24(2):115-25, http://dx.doi.org/10.1055/s-2004-828889.
2. Tyson GL, El-Serag HB. Risk factors for cholangiocar-cinoma. Hepatology (Baltimore, MD) 2011;54(1):173-84, http://dx.doi.org/10.1002/hep.24351.
3. Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM, et al. Resection of hilar cholangiocarcinoma: concomitant liver resec-tion decreases hepatic recurrence. Ann Surg 2008;248(2):273-9, http://dx.doi.org/10.1097/SLA.0b013e31817f2bfd.
4. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bod-niewicz BSJ, et al. Staging, resectability, and outcome in 225 patientswith hilar cholangiocarcinoma. Ann Surg 2001;234(4):507-17 [dis-cussion 517-9].
5. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, et al. Surgical and palliative managementand outcome in 184 patients with hilar cholangiocarci-noma: palliative photodynamic therapy plus stenting iscomparable to r1/r2 resection. Ann Surg 2006;244(2):230-9, http://dx.doi.org/10.1097/01.sla.0000217639.10331.47.
6. Marino D, Leone F, Cavalloni G, Cagnazzo C, AgliettaM. Biliary tract carcinomas: from chemotherapy to tar-geted therapy. Crit Rev Oncol Hematol 2013;85(2):136-48, http://dx.doi.org/10.1016/j.critrevonc.2012.06.006.
7. Pai P, Rachagani S, Are C, Batra SK. Prospects of miRNA-basedtherapy for pancreatic cancer. Curr Drug Targets 2013;14(10):1101-9.
8. Lee RC, Feinbaum RL, Ambros V, The C. elegans heterochronic genelin-4 encodes small RNAs with antisense complementarity to lin-14.Cell 1993;75(5):843-54.
9. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and post-transcriptional gene silencing. Cell 2005;123(4):631-40, http://dx.doi.org/10.1016/j.cell.2005.10.022.
10. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, EachusR, et al. Regulation by let-7 and lin-4 miRNAs resultsin target mRNA degradation. Cell 2005;122(4):553-63, http://dx.doi.org/10.1016/j.cell.2005.07.031.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and func-tion. Cell 2004;116(2):281-97.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature2005;435(7043):834-8, http://dx.doi.org/10.1038/nature03702.
13. Gao Y, Schug J, McKenna LB, Le LJ, Kaestner KH, Green-baum LE. Tissue-specific regulation of mouse microRNA genes inendoderm-derived tissues. Nucleic Acids Res 2011;39(2):454-63, http://dx.doi.org/10.1093/nar/gkq782.
14. Munoz-Garrido P, de Barrena MG, Hijona E, CarracedoM, Marin JJ, Bujanda L, et al. MicroRNAs in biliarydiseases. World J Gastroenterol 2012;18(43):6189-96, http://dx.doi.org/10.3748/wjg.v18.i43.6189.
15. Papaconstantinou I, Karakatsanis A, Gazouli M, Poly-meneas G, Voros D. The role of microRNAs in livercancer. Eur J Gastroenterol Hepatol 2012;24(3):223-8, http://dx.doi.org/10.1097/MEG.0b013e3283505063.
16. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and managementof cholangiocarcinoma. Gastroenterology 2013;145(6):1215-29, http://dx.doi.org/10.1053/j.gastro.2013.10.013.
17. Baker AH, van Rooij E. miRNA overexpression induces car-diomyocyte proliferation in vivo. Mol Ther 2013;21(3):497-8, http://dx.doi.org/10.1038/mt.2013.20.
18. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1protein expression and apoptosis. Oncogene 2007;26(42):6133-40, http://dx.doi.org/10.1038/sj.onc.1210436.
19. Qiu Y, Luo X, Kan T, Zhang Y, Yu W, Wei Y, et al. TGF-beta upregulates miR-182 expression to promote gallblad-der cancer metastasis by targeting CADM1. Mol Biosyst 2014, http://dx.doi.org/10.1039/c3mb70479c.
20. Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, et al. A differential microRNA profile distinguishes cholangiocarcinomafrom pancreatic adenocarcinoma. Ann Surg Oncol 2014;21(1):133-8, http://dx.doi.org/10.1245/s10434-013-3240-y.
21. Kawahigashi Y, Mishima T, Mizuguchi Y, Arima Y, Yoko-muro S, Kanda T, et al. MicroRNA profiling of humanintrahepatic cholangiocarcinoma cell lines reveals biliary epithe-lial cell-specific microRNAs. J Nippon Med Sch 2009;76(4):188-97.
22. Namwat N, Chusorn P, Loilome W, Techasen A, PuetkasichonpasuthaJ, Pairojkul C, et al. Expression profiles of oncomir miR-21 and tumorsuppressor let-7a in the progression of opisthorchiasis-associatedcholangiocarcinoma. Asian Pac J Cancer Prev 2012;13Suppl:65-9.
23. Schultz NA, Werner J, Willenbrock H, Roslind A, GieseN, Horn T, et al. MicroRNA expression profiles asso-ciated with pancreatic adenocarcinoma and ampullaryadenocarcinoma. Mod Pathol 2012;25(12):1609-22, http://dx.doi.org/10.1038/modpathol.2012.122.
24. Chusorn P, Namwat N, Loilome W, Techasen A, Pairojkul C, Khuntikeo N, et al. Overexpression of microRNA-21 regulatingPDCD4 during tumorigenesis of liver fluke-associated cholangio-carcinoma contributes to tumor growth and metastasis. Tumour Biol2013;34(3):1579-88, http://dx.doi.org/10.1007/s13277-013-0688-0.
25. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 pro-motes oncogenesis in intrahepatic cholangiocarcinoma cells via thedirect suppression of RASA1. Exp Ther Med 2013;6(5):1265-70, http://dx.doi.org/10.3892/etm.2013.1311.
26. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changesassociated with cholangiocarcinoma: from DNA methylation tomicroRNAs. World J Gastroenterol 2007;13(48):6465-9.
27. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identifica-tion of mammalian microRNA host genes and transcription units. Genome Res 2004;14(10A):1902-10, http://dx.doi.org/10.1101/gr.2722704.
28. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J2004;23(20):4051-60, http://dx.doi.org/10.1038/sj.emboj.7600385.
29. Vandenboom ITG, Li Y, Philip PA, Sarkar FH. MicroRNA andcancer: Tiny molecules with major implications. Curr Genomics2008;9(2):97-109, http://dx.doi.org/10.2174/138920208784139555.
30. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Process-ing of primary microRNAs by the microprocessor complex. Nature2004;432(7014):231-5, http://dx.doi.org/10.1038/nature03049.
31. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. Thenuclear RNase III Drosha initiates microRNA processing. Nature2003;425(6956):415-9, http://dx.doi.org/10.1038/nature01957.
32. Kim VN. MicroRNA precursors in motion: exportin-5 mediates theirnuclear export. Trends Cell Biol 2004;14(4):156-9.
33. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclearexport of microRNA precursors. Science (New York, NY)2004;303(5654):95-8, http://dx.doi.org/10.1126/science.1090599.
34. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathwaysand their regulation. Nat Cell Biol 2009;11(3):228-34, http://dx.doi.org/10.1038/ncb0309-228.
35. Bahubeshi A, Tischkowitz M, Foulkes WD. miRNAprocessing and human cancer: DICER1 cuts themustard. Sci Transl Med 2011;3(111):111ps46, http://dx.doi.org/10.1126/scitranslmed.3002493.
36. Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K, et al. MicroRNAs in hepatobiliary and pancreatic cancers. Front Genet2011;2:66, http://dx.doi.org/10.3389/fgene.2011.00066.
37. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms ofmicroRNA deregulation in human cancer. Cell Cycle (Georgetown, TX) 2008;7(17):2643-6.
38. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 inmalignant human cholangiocytes. Oncogene 2008;27(3):378-86, http://dx.doi.org/10.1038/sj.onc.1210648.
39. An F, Yamanaka S, Allen S, Roberts LR, Gores GJ, PawlikTM, et al. Silencing of miR-370 in human cholangiocarci-noma by allelic loss and interleukin-6 induced maternal topaternal epigenotype switch. PLoS ONE 2012;7(10):e45606, http://dx.doi.org/10.1371/journal.pone.0045606.
40. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT.c-Myc-regulated microRNAs modulate E2F1 expression. Nature2005;435(7043):839-43, http://dx.doi.org/10.1038/nature03677.
41. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators inthe hallmarks of human cancer. Cancer Lett 2009;285(2):116-26, http://dx.doi.org/10.1016/j.canlet.2009.04.031.
42. Calin GA, Croce CM. MicroRNA-cancer connection: thebeginning of a new tale. Cancer Res 2006;66(15):7390-4, http://dx.doi.org/10.1158/0008-5472.CAN-06-0800.
43. Kim VN. MicroRNA biogenesis: coordinated croppingand dicing. Nat Rev Mol Cell Biol 2005;6(5):376-85, http://dx.doi.org/10.1038/nrm1644.
44. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs asoncogenes and tumor suppressors. Dev Biol 2007;302(1):1-12, http://dx.doi.org/10.1016/j.ydbio.2006.08.028.
45. Dalmay T, Edwards DR. MicroRNAs and the hall-marks of cancer. Oncogene 2006;25(46):6170-5, http://dx.doi.org/10.1038/sj.onc.1209911.
46. TischoffI, Wittekind C, Tannapfel A. Role of epigenetic alter-ations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg2006;13(4):274-9, http://dx.doi.org/10.1007/s00534-005-1055-3.
47. Isomoto H. Epigenetic alterations associated with cholangiocarci-noma (review). Oncol Rep 2009;22(2):227-32.
48. Hong L, Han Y, Li S, Yang J, Zheng J, Zhang H, et al. The malignant phenotype-associated microRNAin gastroenteric, hepatobiliary and pancreatic carcino-mas. Expert Opin Biol Ther 2010;10(12):1693-701, http://dx.doi.org/10.1517/14712598.2010.532482.
49. Mott JL. MicroRNAs involved in tumor suppressor andoncogene pathways: implications for hepatobiliary neo-plasia. Hepatology (Baltimore, MD) 2009;50(2):630-7, http://dx.doi.org/10.1002/hep.23010.
50. Wong KY, Yu L, Chim CS. DNA methylation of tumor suppres-sor miRNA genes: a lesson from the miR-34 family. Epigenomics2011;3(1):83-92, http://dx.doi.org/10.2217/epi.10.74.
51. Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinomagrowth by activating beta-catenin. Gastroenterology 2012;143(1), http://dx.doi.org/10.1053/j.gastro.2012.03.045,246-56.e8.
52. Zhong XY, Yu JH, Zhang WG, Wang ZD, Dong Q, Tai S, et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract can-cer through down-regulating farnesoid X receptor expression. Gene2012;493(1):44-51, http://dx.doi.org/10.1016/j.gene.2011.11.028.
53. Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, et al. MiR-20a triggersmetastasis of gallbladder carcinoma. J Hepatol 2013;59(3):518-27, http://dx.doi.org/10.1016/j.jhep.2013.04.034.
54. Razumilava N, Bronk SF, Smoot RL, Fingas CD, WerneburgNW, Roberts LR, et al. miR-25 targets TNF-related apoptosisinducing ligand (TRAIL) death receptor-4 and promotes apopto-sis resistance in cholangiocarcinoma. Hepatology (Baltimore, MD)2012;55(2):465-75, http://dx.doi.org/10.1002/hep.24698.
55. Kono H, Nakamura M, Ohtsuka T, Nagayoshi Y, Mori Y, TakahataS, et al. High expression of microRNA-155 is associated with theaggressive malignant behavior of gallbladder carcinoma. Oncol Rep2013;30(1):17-24, http://dx.doi.org/10.3892/or.2013.2443.
56. Yang W, Wang X, Zheng W, Li K, Liu H, Sun Y. Geneticepigenetic alterations are involved in the regulation ofTPM1 in cholangiocarcinoma. Int J Oncol 2013;42(2):690-8, http://dx.doi.org/10.3892/ijo.2012.1741.
57. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma andregulates programmed cell death 4 and tissue inhibitor of metal-loproteinase 3. Hepatology (Baltimore, MD) 2009;49(5):1595-601, http://dx.doi.org/10.1002/hep.22838.
58. He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, et al. Ars2 is overex-pressed in human cholangiocarcinomas and its depletion increasesPTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog2013;52(4):286-96, http://dx.doi.org/10.1002/mc.21859.
59. Liu CZ, Liu W, Zheng Y, Su JM, Li JJ, Yu L, et al. PTEN and PDCD4are bona fide targets of microRNA-21 in human cholangiocarcinoma. Chin Med Sci J 2012;27(2):65-72.
60. Huang Q, Liu L, Liu CH, You H, Shao F, Xie F, et al. MicroRNA-21regulates the invasion and metastasis in cholangiocarcinoma and maybe a potential biomarker for cancer prognosis. Asian Pac J CancerPrev 2013;14(2):829-34.
61. Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, et al. miR-29 acts as a decoy in sarcomas to protect thetumor suppressor A20 mRNA from degradation by HuR. Sci Signal2013;6(286), http://dx.doi.org/10.1126/scisignal.2004177,ra63.
62. Park SY, Lee JH, Ha M, Nam JW. Kim VN. miR-29 miRNAs acti-vate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol2009;16(1):23-9, http://dx.doi.org/10.1038/nsmb.1533.
63. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressorin CLL. Oncotarget 2010;1(3):224-7.
64. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J CellBiochem 2010;110(5):1155-64, http://dx.doi.org/10.1002/jcb.22630.
65. Zhang J, Han C, Zhu H, Song K, Wu T. miR-101 inhibits cholan-giocarcinoma angiogenesis through targeting vascular endothelialgrowth factor (VEGF). Am J Pathol 2013;182(5):1629-39, http://dx.doi.org/10.1016/j.ajpath.2013.01.045.
66. Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, et al. Direct target-ing of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinomatumourigenesis and metastasis. Br J Cancer 2013;109(12):3092-104, http://dx.doi.org/10.1038/bjc.2013.655.
67. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, PopescuI, et al. MicroRNA down-regulated in human cholangiocarci-noma control cell cycle through multiple targets involved in theG1/S checkpoint. Hepatology (Baltimore, MD) 2011;54(6):2089-98, http://dx.doi.org/10.1002/hep.24591.
68. Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, MezeyE, et al. Coordinated effects of microRNA-494 induce G(2)/Marrest in human cholangiocarcinoma. Cell Cycle (Georgetown, TX)2012;11(14):2729-38, http://dx.doi.org/10.4161/cc.21105.
69. Wang Q, Tang H, Yin S, Dong C. Downregulation ofmicroRNA-138 enhances the proliferation, migration and inva-sion of cholangiocarcinoma cells through the upregulation ofRhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 2013;29(5):2046-52, http://dx.doi.org/10.3892/or.2013.2304.
70. Iwaki J, Kikuchi K, Mizuguchi Y, Kawahigashi Y, Yoshida H, UchidaE, et al. MiR-376c down-regulation accelerates EGF-dependentmigration by targeting GRB2 in the HuCCT1 human intrahep-atic cholangiocarcinoma cell line. PLOS ONE 2013;8(7):e69496, http://dx.doi.org/10.1371/journal.pone.0069496.
71. Zeng B, Li Z, Chen R, Guo N, Zhou J, Zhou Q, et al. Epi-genetic regulation of miR-124 by hepatitis C virus core proteinpromotes migration and invasion of intrahepatic cholangiocarci-noma cells by targeting SMYD3. FEBS Lett 2012;586(19):3271-8, http://dx.doi.org/10.1016/j.febslet.2012.06.049.
72. Chen Y, Gao W, Luo J, Tian R, Sun H, Zou S. Methyl-CpGbinding protein MBD2 is implicated in methylation-mediated sup-pression of miR-373 in hilar cholangiocarcinoma. Oncol Rep2011;25(2):443-51, http://dx.doi.org/10.3892/or.2010.1089.
73. Chen Y, Luo J, Tian R, Sun H, Zou S. miR-373 nega-tively regulates methyl-CpG-binding domain protein 2 (MBD2)in hilar cholangiocarcinoma. Dig Dis Sci 2011;56(6):1693-701, http://dx.doi.org/10.1007/s10620-010-1481-1.
74. Braconi C, Huang N, Patel T. MicroRNA-dependent reg-ulation of DNA methyltransferase-1 and tumor suppressorgene expression by interleukin-6 in human malignant cholan-giocytes. Hepatology (Baltimore, MD) 2010;51(3):881-90, http://dx.doi.org/10.1002/hep.23381.
75. Yang H, Li TW, Peng J, Tang X, Ko KS, Xia M, et al. A mouse modelof cholestasis-associated cholangiocarcinoma and transcription fac-tors involved in progression. Gastroenterology 2011;141(1):378-88, http://dx.doi.org/10.1053/j.gastro.2011.03.044,388.e1-4.
76. Meng F, Wu G. The rejuvenated scenario ofepithelial-mesenchymal transition (EMT) and cancermetastasis. Cancer Metastasis Rev 2012;31(3-4):455-67, http://dx.doi.org/10.1007/s10555-012-9379-3.
77. Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, et al. miR-204 Inhibits Epithelial to Mesenchymal Transition by Targeting Slugin Intrahepatic Cholangiocarcinoma Cells. Cell Physiol Biochem2013;32(5):1331-41, http://dx.doi.org/10.1159/000354531.
78. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinomametastasis by targeting Twist. FEBS J 2012;279(13):2393-8, http://dx.doi.org/10.1111/j.1742-4658.2012.08618.x.
79. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et al. Transcriptomic profiling reveals hepatic stem-like gene signaturesand interplay of miR-200c and epithelial-mesenchymal transitionin intrahepatic cholangiocarcinoma. Hepatology (Baltimore, MD)2012;56(5):1792-803, http://dx.doi.org/10.1002/hep.25890.
80. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology2005;128(6):1655-67.
81. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current manage-ment of gallbladder carcinoma. Oncologist 2010;15(2):168-81, http://dx.doi.org/10.1634/theoncologist.2009-0302.
82. Sandanayake NS, Sinclair J, Andreola F, Chapman MH, XueA, Webster GJ, et al. A combination of serum leucine-richalpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate bil-iary tract cancer from benign biliary strictures. Br J Cancer2011;105(9):1370-8, http://dx.doi.org/10.1038/bjc.2011.376.
83. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatmentof cholangiocarcinoma: consensus document. Gut 2002;51(Suppl.6):VI1-9.
84. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Circulating microR-NAs as potential new biomarkers for prostate cancer. Br J Cancer2013;108(10):1925-30, http://dx.doi.org/10.1038/bjc.2013.192.
85. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of microRNA expression pattern in human intra-hepatic cholangiocarcinoma. J Hepatol 2009;50(2):358-69, http://dx.doi.org/10.1016/j.jhep.2008.09.015.
86. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stableblood-based markers for cancer detection. Proc Natl Acad Sci U S A2008;105(30):10513-8, http://dx.doi.org/10.1073/pnas.0804549105.
87. Kishimoto T, Eguchi H, Nagano H, Kobayashi S, Akita H, Hama N, et al. Plasma miR-21 is a novel diagnostic biomarkerfor biliary tract cancer. Cancer Sci 2013;104(12):1626-31, http://dx.doi.org/10.1111/cas.12300.
88. Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, ArimaY, Kawahigashi Y, et al. Real-time PCR-based analysis of thehuman bile microRNAome identifies miR-9 as a potential diagnos-tic biomarker for biliary tract cancer. PLoS ONE 2011;6(8):e23584, http://dx.doi.org/10.1371/journal.pone.0023584.
89. Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, et al. Human bile contains microRNA-laden extracellular vesicles that canbe used for cholangiocarcinoma diagnosis. Hepatology (Baltimore, MD) 2014, http://dx.doi.org/10.1002/hep.27050.
90. Hong L, Han Y, Zhang H, Zhao Q, Qiao Y. miR-210: a thera-peutic target in cancer. Expert Opin Ther Targets 2013;17(1):21-8, http://dx.doi.org/10.1517/14728222.2012.732066.
91. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA CancerJ Clin 2012;62(1):10-29, http://dx.doi.org/10.3322/caac.20138.
92. Fesler A, Zhai H, Ju J. miR-129 as a novel therapeutic tar-get and biomarker in gastrointestinal cancer. Onco Targets Ther2014;7:1481-5, http://dx.doi.org/10.2147/OTT.S65548.
93. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors andmodifiers of chemo-and radiotherapy in different tumour types. Eur J Cancer (Oxford, England: 1990) 2010;46(2):298-311, http://dx.doi.org/10.1016/j.ejca.2009.10.027.
94. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA ingrowth and response to chemotherapy in human cholangio-carcinoma cell lines. Gastroenterology 2006;130(7):2113-29, http://dx.doi.org/10.1053/j.gastro.2006.02.057.
95. Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 andmiR-221 enhance chemosensitivity to gemcitabine in HuH28human cholangiocarcinoma cells. PLOS ONE 2013;8(10):e77623, http://dx.doi.org/10.1371/journal.pone.0077623.
96. Lee HK, Cho MS, Kim TH. Prognostic significance of muc4 expres-sion in gallbladder carcinoma. World J Surg Oncol 2012;10:224, http://dx.doi.org/10.1186/1477-7819-10-224.
97. Peng HH, Zhang YD, Gong LS, Liu WD, Zhang Y. Increasedexpression of microRNA-335 predicts a favorable prognosis in pri-mary gallbladder carcinoma. Onco Targets Ther 2013;6:1625-30, http://dx.doi.org/10.2147/OTT.S53030.
98. Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, et al. miR-34 is associ-ated with poor prognosis of patients with gallbladder cancer throughregulating telomere length in tumor stem cells. Tumour Biol 2013, http://dx.doi.org/10.1007/s13277-013-1207-z.
99. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, andmiR-223 in patients with hepatocellular carcinoma or intrahepaticcholangiocarcinoma and its prognostic significance. Mol Carcinog2013;52(4):297-303, http://dx.doi.org/10.1002/mc.21864.
100. McNally ME, Collins A, Wojcik SE, Liu J, Henry JC, Jiang J, et al. Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival inresected cholangiocarcinoma. HPB (Oxford) 2013;15(4):260-4, http://dx.doi.org/10.1111/j.1477-2574.2012.00523.x.